Levetiracetam;Levetiracetam

Neurologia

Volumn 16, Issue 9, 2001, Pages 427-432

  Salas Puig, J ^a   Calleja, S ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Antiepileptic drugs; Epilepsy; Levetiracetam; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIGOXIN; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROBENECID; VALPROIC ACID; WARFARIN;

ANTICONVULSANT THERAPY; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; REVIEW; SEIZURE; SOMNOLENCE; VERTIGO;

ADULT; ANIMALS; ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSIES, PARTIAL; HUMANS; LEARNING; MEMORY; MOLECULAR STRUCTURE; PIRACETAM;

EID: 0035720044     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 through 1984
2. Remission of epilepsy: Results from the national general practice study of epilepsy
3. Ucb L059, a novel anticonvulsivant drug: Pharmacological profile in animals
4. Levetiracetam. A review of its adjunctive use in the management of partial onset seizures
5. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
6. Ucb L059, a novel anticonvulsivante drug, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo
7. Inhibition by levetiracetam of a non-GABA(A) receptor-associated epileptiform effect of bicuculline in rat hippocampus
8. Effects of ucb L059, a potential anticonvulsant agent, on release of dopamine (DA) and its metabolites from cerebral ventricular perfusate induced by bicuculline (BIC) and haloperidol (HAL) in rats
9. Effect of levetiracetam on voltage-gated potassium channels: A novel antiepileptic mechanism of action?
10. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes
11. Antiepileptogenic effects of the novel anticonvulsivant levetiracetam (ucb L059) in the kindling model of temporal lobe epilesy
12. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats
13. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam
14. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
15. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent
16. Enzyme induction and inhibition by new antiepileptic drugs: A review of human studies
17. Mechanism of interaction between ucb L059 and phenytoin
18. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique
19. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
20. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures
21. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial onset seizures: A multicenter double-blind, responder-selected study evaluating monotherapy
22. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy
23. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy (Cochrane Review)
24. Long-term continuation of levetiracetam in patients with refractory epilepsy
25. Effect of levetiracetam on epilepsy-related quality of life
26. Open-label efficacy and safety of levetiracetam in pediatric patients with partial onset seizures
27. Photosensitive epilepsy: A model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam
28. Supression of post-hypoxic and post-encephalitic myoclonus with levetiracetam
29. Antimyoclonic effect of levetiracetam
30. The effect of add on therapy with levetiracetam (ucb L059) on patients with resistant juvenile myoclonic epilepsy
31. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia
32. Piracetam for choreoathetosis